Clinical Trial Update: A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase II exploratory neoadjuvant trial evaluating the combination of Iparomlimab and Tuvonralimab with chemotherapy in HR+/HER2- breast cancer; the study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Anhui Provincial Cancer Hospital | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING